Nutra Pharma CORP

Nutra Pharma Corp. announced a change in control on August 21, 2026, with Pure Raw Supplies, LLC acquiring controlling voting power through a gift of Series B Preferred Stock.

Nutra Pharma Corp. announced the resignation of Marcum LLP as its independent auditor and the appointment of Astra Audit & Advisory, citing material weaknesses in internal controls.

Nutra Pharma Corp. has announced the resignation of its CEO, Rik J. Deitsch, following a settlement with the SEC, and the appointment of Dr. Michael Flax as the new CEO, Chairman, and CFO.

Nutra Pharma Corp. filed its Q2 2026 Form 10-Q, revealing substantial net losses, increased operating expenses, and a precarious liquidity position, with significant debt defaults continuing.

Nutra Pharma Corp. reports a net loss of $459,675 for Q1 2026, citing ongoing liquidity challenges and significant debt defaults.

Nutra Pharma Corp. reported a wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and fluctuations in derivative liabilities, despite a rise in net sales to unrelated customers.

Nutra Pharma Corp. reported a net income of $369,577 for Q2 2025, driven by non-operating gains, despite ongoing substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and debt defaults.

Nutra Pharma Corp. reported a widened net loss for Q2 2024 and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reported a significant net loss and declining revenues for Q1 2024, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reports significant net losses and substantial doubt regarding its ability to continue as a going concern in its 2025 annual report.

Nutra Pharma Corp. reported continued net losses and a significant working capital deficit for fiscal year 2024, raising substantial doubt about its ability to continue as a going concern, while also settling a major SEC lawsuit.

Nutra Pharma Corp. reported a net loss of $1.39 million in 2023, a significant decline from the prior year's net income, while settling an SEC lawsuit and undergoing a CEO transition.

Nutra Pharma Corp. reported a net income of $8.18 million for 2022, primarily driven by a non-cash gain from derivative revaluation, while facing a significant SEC settlement and a change in executive leadership.

Rik J Deitsch, a 10% owner of Nutra Pharma Corp, reported a transaction in 12,000,000 shares of common stock on August 21, 2026.

Pure Raw Supplies LLC reports acquiring 100% of Nutra Pharma Corp's Series B Preferred Shares via a gift, holding them for investment purposes.